Publication:
Botulinum toxin in poststroke spasticity

dc.contributor.authorÖzçakır, Şüheda
dc.contributor.authorSivrioğlu, Koncuy
dc.contributor.buuauthorÖZÇAKIR, ŞÜHEDA
dc.contributor.buuauthorSİVRİOĞLU, KONÇUY
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentFiziksel Tıp ve Rehabilitasyon Ana Bilim Dalı
dc.contributor.orcid0000-0002-4296-9480
dc.contributor.researcheridAAH-5375-2021
dc.contributor.researcheridAAG-8211-2021
dc.date.accessioned2024-09-25T06:24:04Z
dc.date.available2024-09-25T06:24:04Z
dc.date.issued2007-06-01
dc.description.abstractPoststroke hemiparesis, together with abnormal muscle tone, is a major cause of morbidity and disability. Although most hemiparetic patients are able to reach different ambulatory levels with rehabilitation efforts, upper and lower limb spasticity can impede activities of daily living, personal hygiene, ambulation and, in some cases, functional improvement. The goals of spasticity management include increasing mobility and range of motion, attaining better hygiene, improving splint wear and other functional activities. Conservative measures, such as positioning, stretching and exercise are essential in spasticity management, but alone often are inadequate to effectively control it. Oral antispastic medications often provide limited effects with short duration and frequent unwanted systemic side effects, such as weakness, sedation and dry mouth. Therefore, neuromuscular blockade by local injections have become the first choice for the treatment of focal spasticity, particularly in stroke patients. Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles. Two antigenically distinct serotypes of BTX are available on the market as type A and B. Clinical studies of BTX used for spastic hemiplegic patients are reviewed in this article in two major categories, upper and lower limb applications. This review addresses efficacy in terms of outcome measures, such as muscle tone reduction and functional outcome, as well as safety issues. Application modifications of dose, dilutions, site of injections and combination therapies with BTX injections are also discussed.
dc.identifier.doi10.3121/cmr.2007.716
dc.identifier.eissn1554-6179
dc.identifier.endpage138
dc.identifier.issn1539-4182
dc.identifier.issue2
dc.identifier.startpage132
dc.identifier.urihttps://doi.org/10.3121/cmr.2007.716
dc.identifier.urihttp://www.clinmedres.org/content/5/2/132
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905930/
dc.identifier.urihttps://hdl.handle.net/11452/45190
dc.identifier.volume5
dc.identifier.wos000210084000008
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherMarshfield Clinic
dc.relation.journalClinical Medicine & Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBotulinum toxin
dc.subjectSpasticity
dc.subjectStroke
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectMedicine, general & internal
dc.subjectGeneral & internal medicine
dc.titleBotulinum toxin in poststroke spasticity
dc.typeReview
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Ana Bilim Dalı
relation.isAuthorOfPublicationf95ede00-3383-4693-9b74-6ab1cbb3599d
relation.isAuthorOfPublication7b88ed11-688c-4444-af3b-91b21030df32
relation.isAuthorOfPublication.latestForDiscoveryf95ede00-3383-4693-9b74-6ab1cbb3599d

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Özçakır_Sivrioğlu_2007.pdf
Size:
245.29 KB
Format:
Adobe Portable Document Format

Collections